Table 5.
Cancer-specific mortality
| Overall, n = 459 Adjusted SHR (95% CI) |
Ovarian cancer, n = 186 Adjusted SHR (95% CI) |
Endometrial cancer, n = 219 Adjusted SHR (95% CI) |
|
|---|---|---|---|
| Comorbidity | |||
| CCI 0 | Ref. | Ref. | Ref. |
| CCI 1–2 | 1.2 (0.8–1.6) | 1.1 (0.7–1.6) | 1.2 (0.5–2.9) |
| CCI 3+ | 1.1 (0.4–2.5) | 0.7 (0.2–2.4) | 1.8 (0.4–8.1) |
| FIGO stage | |||
| I | Ref. | Ref. | Ref. |
| II–III | 2.7 (1.4–5.0) | 3.1 (1.2–8.5) | 1.8 (0.7–4.8) |
| IV | 4.2 (2.0–8.6) | 4.7 (1.7–13.3) | 4.6 (0.7–31.7) |
| Age, years | |||
| 70–74 | Ref. | Ref. | Ref. |
| 75–79 | 1.3 (0.9–2.0) | 1.3 (0.8–1.9) | 1.7 (0.6–4.9) |
| 80–84 | 1.5 (0.9–2.6) | 2.0 (1.0–3.9) | 1.4 (0.5–4.0) |
| ≥ 85 | 1.3 (0.6–2.9) | 0.5 (0.1–2.1) | 2.0 (0.5–7.8) |
| Treatment choice | |||
| Curative treatment | Ref. | Ref. | Ref. |
| Palliative treatment | 2.1 (1.4–3.2) | 2.1 (1.3–3.3) | 1.8 (0.5–6.2) |
| No treatment | 5.1 (2.4–10.9) | 10.2 (4.2–24.8) | 1.3 (0.1–22.2) |
| Diagnosis | |||
| Ovarian cancer | Ref. | – | – |
| Endometrial cancer | 0.5 (0.3–0.8) | – | – |
| Cervical cancer | 0.3 (0.1–0.6) | – | – |
| Performance status | |||
| 0 | Ref. | Ref. | Ref. |
| 1 | 1.1 (0.7–1.5) | 1.0 (0.7–1.5) | 0.5 (0.2–1.5) |
| 2 | 1.0 (0.5–1.7) | 0.7 (0.4–1.3) | 1.5 (0.4–5.9) |
| 3 | 0.5 (0.2–1.8) | 0.2 (0.0–1.5) | 2.3 (0.4–13.5) |
| 4 | 9.3 (2.8–31.0) | 6.6 (2.5–17.3) | – |
Bolded values represent statistically significant results
Note: Competing risk analysis with adjustment for all listed variables. Analysis was not possible for cervical cancer because of a low number of patients
CCI Charlson Comorbidity Index, CI confidence interval, FIGO International Federation of Gynecology and Obstetrics, SHR sub-hazard ratio, Ref. reference